Price to Earnings (P/E)
since 2005
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Common-Size Balance Sheet: Assets
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Selected Financial Data since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Vertex Pharmaceuticals Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income (loss)1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 10, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2014 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 16, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Vertex Pharmaceuticals Inc. Annual Report.
- Share Price Trend
- The share price exhibits significant variability over the observed periods. Starting at $39.49 in 2006, it initially declined to a low of $18.21 in early 2008. From 2009 onwards, there is a general upward trend, with notable increases beginning in 2013. The share price more than doubled from $84.98 in 2014 to $185.25 in 2019, reaching a peak of $462.58 by early 2025. Despite some fluctuations, the overall trajectory is strongly positive, signaling an appreciation in market valuation over time.
- Earnings per Share (EPS) Trend
- EPS data reveals a challenging period for profitability from 2006 through 2011, with consistent negative values reaching as low as -$3.69 in 2011. A turning point appears around 2012 when EPS becomes slightly positive but fluctuates back to negative in subsequent years until 2014. From 2015 onward, the EPS trend becomes more robustly positive, peaking at $14.01 in 2024. However, an anomalous decline to -$2.09 in 2025 suggests either a one-time event or volatility in earnings for the most recent period. The overall trend illustrates an improvement from losses to profitability over the long term, albeit with some short-term fluctuations.
- Price-to-Earnings (P/E) Ratio Analysis
- The P/E ratio data, albeit sparse, shows extremely high values during periods of positive earnings. For example, in 2012, the P/E is recorded at 267.42, indicating elevated market expectations or possibly low earnings driving the ratio high. The P/E ratio decreases to more moderate levels between 20 and 30 from 2018 to 2024, aligning with improved earnings performance. Sharp declines or missing data in other years preclude a continuous analysis, but the available data suggests the market price has generally remained high relative to earnings, consistent with growth prospects or investor optimism.
- Overall Financial Performance Insights
- The financial metrics reflect a transition from periods of sustained losses to strong earnings growth over the nearly two-decade span. The share price appreciation corroborates improved financial standing and investor confidence. Notably, the EPS volatile behavior around 2025 indicates that recent performance may face challenges. The high P/E ratios during earlier positive earnings years imply that investors were willing to pay premiums for growth potential. The interplay of these factors suggests a maturing firm moving from development-phase losses toward profitability, with recent data pointing to the necessity for monitoring upcoming earnings trends closely.
Comparison to Competitors
Vertex Pharmaceuticals Inc., P/E, long-term trends, comparison to competitors
| Vertex Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2025 | ||||||||||||
| Feb 15, 2024 | ||||||||||||
| Feb 10, 2023 | ||||||||||||
| Feb 9, 2022 | ||||||||||||
| Feb 11, 2021 | ||||||||||||
| Feb 13, 2020 | ||||||||||||
| Feb 13, 2019 | ||||||||||||
| Feb 15, 2018 | ||||||||||||
| Feb 23, 2017 | ||||||||||||
| Feb 16, 2016 | ||||||||||||
| Feb 13, 2015 | ||||||||||||
| Feb 11, 2014 | ||||||||||||
| Mar 1, 2013 | ||||||||||||
| Feb 22, 2012 | ||||||||||||
| Feb 17, 2011 | ||||||||||||
| Feb 19, 2010 | ||||||||||||
| Feb 17, 2009 | ||||||||||||
| Feb 11, 2008 | ||||||||||||
| Mar 1, 2007 | ||||||||||||
| Mar 16, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Vertex Pharmaceuticals Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Vertex Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 13, 2025 | ||
| Feb 15, 2024 | ||
| Feb 10, 2023 | ||
| Feb 9, 2022 | ||
| Feb 11, 2021 | ||
| Feb 13, 2020 | ||
| Feb 13, 2019 | ||
| Feb 15, 2018 | ||
| Feb 23, 2017 | ||
| Feb 16, 2016 | ||
| Feb 13, 2015 | ||
| Feb 11, 2014 | ||
| Mar 1, 2013 | ||
| Feb 22, 2012 | ||
| Feb 17, 2011 | ||
| Feb 19, 2010 | ||
| Feb 17, 2009 | ||
| Feb 11, 2008 | ||
| Mar 1, 2007 | ||
| Mar 16, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Vertex Pharmaceuticals Inc., P/E, long-term trends, comparison to industry (health care)
| Vertex Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Feb 13, 2025 | ||
| Feb 15, 2024 | ||
| Feb 10, 2023 | ||
| Feb 9, 2022 | ||
| Feb 11, 2021 | ||
| Feb 13, 2020 | ||
| Feb 13, 2019 | ||
| Feb 15, 2018 | ||
| Feb 23, 2017 | ||
| Feb 16, 2016 | ||
| Feb 13, 2015 | ||
| Feb 11, 2014 | ||
| Mar 1, 2013 | ||
| Feb 22, 2012 | ||
| Feb 17, 2011 | ||
| Feb 19, 2010 | ||
| Feb 17, 2009 | ||
| Feb 11, 2008 | ||
| Mar 1, 2007 | ||
| Mar 16, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).